Possible scenario
Measured Commercial Ramp
30% Chance
Juvmo launches successfully but faces normal payer scrutiny, physician caution, and competition from established Parkinson's regimens. Revenue expectations rise, but not enough to materially change AbbVie's near-term group outlook.
Tickers
- ABBV+2.1%
- AMRX+0.3%
- SUPN+0.3%
- CVS+0.1%
- CI+0.1%
Portfolio impact
S&P 500+0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.